About coeptis therapeutics holdings inc - COEP
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. It operates through the Biotechnology and Technology segments. The Biotechnology segment is involved in developing biotechnology product pipelines. The Technology segment relates to acquiring technology assets to support and enhance operational capabilities through advanced technologies. The company was founded in 2017 and is headquartered in Wexford, PA.
COEP At a Glance
Coeptis Therapeutics Holdings, Inc.
105 Bradford Road
Wexford, Pennsylvania 15090
| Phone | 1-724-934-6467 | Revenue | 1.36M | |
| Industry | Biotechnology | Net Income | -11,917,015.00 | |
| Sector | Health Technology | Employees | 6 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
COEP Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 44.273 |
| Price to Book Ratio | 4.748 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.633 |
| Enterprise Value to Sales | 40.182 |
| Total Debt to Enterprise Value | 0.005 |
COEP Efficiency
| Revenue/Employee | 227,174.167 |
| Income Per Employee | -1,986,169.167 |
| Receivables Turnover | 185.499 |
| Total Asset Turnover | 0.088 |
COEP Liquidity
| Current Ratio | 4.157 |
| Quick Ratio | 4.157 |
| Cash Ratio | 3.592 |
COEP Profitability
| Gross Margin | -207.81 |
| Operating Margin | -956.938 |
| Pretax Margin | -900.718 |
| Net Margin | -874.294 |
| Return on Assets | -77.26 |
| Return on Equity | -105.771 |
| Return on Total Capital | -68.03 |
| Return on Invested Capital | -104.295 |
COEP Capital Structure
| Total Debt to Total Equity | 1.559 |
| Total Debt to Total Capital | 1.535 |
| Total Debt to Total Assets | 1.355 |
| Long-Term Debt to Equity | 0.87 |
| Long-Term Debt to Total Capital | 0.856 |